Last reviewed · How we verify
ACA 125
At a glance
| Generic name | ACA 125 |
|---|---|
| Sponsor | AGO Study Group |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (PHASE1)
- Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (PHASE2, PHASE3)
- Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACA 125 CI brief — competitive landscape report
- ACA 125 updates RSS · CI watch RSS
- AGO Study Group portfolio CI